Metformin treatment is associated with reduced risk of hypoglycaemia, major adverse cardiovascular events, and all-cause mortality in patients with post-pancreatitis diabetes mellitus: a nationwide cohort study.

Line Davidsen Morten Hasselstrøm Jensen Mathias Ellgaard CookPeter VestergaardFilip K Krag Knop Asbjørn Mohr Drewes Søren Schou Olesen

Published in: European journal of endocrinology (2024)

Metformin is associated with a lower risk of adverse outcomes, including all-cause mortality in patients with PPDM, supporting the use of metformin as a glucose-lowering therapy for these patients.

Keyphrases

cardiovascular events
coronary artery disease
end stage renal disease
ejection fraction
newly diagnosed
cardiovascular disease
prognostic factors
emergency department
blood pressure
patient reported
replacement therapy
electronic health record
adverse drug